بسم الله الرحمن الرحیم Cataract & Diabetes Mellitus.

Slides:



Advertisements
Similar presentations
F. Kianersi M.D 1387 / 12 / 1.  Patients with uveitis have cataracts: More often, and at an Earlier Age than the general population.  Main etiological.
Advertisements

1 ICD-9-CM Coordination and Maintenance Committee Meeting October 8 th, 2004 Matthew J. Sheetz, MD, PhD Promoting Clear Identification of Diabetic Retinopathy.
The Diabetic Retinopathy Clinical Research Network
Evan (Jake) Waxman MD PhD
YAG capsulotomy K.P.SHANTHA SORUBARANI.
INTRA-OPERATIVE MANAGEMENT OF CATARACT SURGERY COMPLICATIONS Dr. H. Razmjoo Isfahan University of Medical Sciences.
The Diabetic Retinopathy Clinical Research Network Effects of Intravitreal Ranibizumab or Triamcinolone on Diabetic Retinopathy Jennifer K. Sun, MD, MPH.
GH.Naderian, M.D.. Supra choroidal hemorrhage Cystoid macular edema Retinal detachment.
CATARACT SUEGRY AND DIABETES Indications of surgery: 1) Visual loss 2)Surveillance of retinopathy 3)Laser therapy.
Anti VEGF Options in the management of CNV 1)Observation  occult CNV also requires close follow – up.every 3 month 2) Laser coagulation 3) Surgery.
Intraocular lens (IOL) Dislocation M.R. Akhlaghi MD.
F. Kianersi M.D 1387 / 12 / 1.  Diabetes mellitus presently afflicts an estimated 20.2 million Americans, with expectations of over 30 million cases.
Katsuya Yamazoe, MD, Takefumi Yamaguchi, MD, Kazuki Hotta, MD, Yoshiyuki Satake, MD, Kenji Konomi, MD, Seika Den, MD, Jun Shimazaki, MD Presented by: Abdulrahman.
DIABETES AND EYE DISEASE: LEARNING OBJECTIVES
Yüksel Totan, Ramazan Yaĝcı, Zeynel Arslanyılmaz, Uĝurcan Keskin The authors have no financial interest.
Vitrectomy Outcomes in Eyes with Diabetic Macular Edema, Visual Loss, and Vitreomacular Traction Sponsored by the National Eye Institute, National Institutes.
Copyright restrictions may apply JAMA Ophthalmology Journal Club Slides: Macular Edema After Cataract Surgery Diabetic Retinopathy Clinical Research Network.
Phaco in post- vitrectomy cataracts George Kampougeris MD, MRCSEd, PhD Consultant Ophthalmic Surgeon
Diagnosis & Management of Diabetic Eye Disease A. Paul Chous, M.A., O.D., F.A.A.O. Tacoma, WA Specializing in Diabetes Eye Care & Education Part 6.
Diabetes and the Eye Karen B. Saland, M.D. August 18, 2008.
A Randomized Trial of Peribulbar Triamcinolone Acetonide with and without Focal Photocoagulation for Mild Diabetic Macular Edema: A Pilot Study.
The Diabetic Retinopathy Clinical Research Network
Dr. Thiruvengada Krishnan , M.D. , Aravind Eye Hospital
Josephine Carlos-Raboca, M.D. Makati Medical Center
RETINOPATHY 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
Alexander J. Brucker, M.D. Protocol Chair
Multifocal Intraocular Lenses Abdullah Al-assiri Mansour Farooqui Abdulrahman Al-Muammar Saudi Ophthalmology Meeting 2009.
Ki-Cheol Chang, MD Department of Ophthalmology, Dankook University Hospital, South Korea Financial disclosure : Author has no commercial associations.
Chronic Visual Loss. CHRONIC VISUAL LOSS 1. Measure intraocular pressure with a tonometer 2. Evaluate the nerve head 3. Evaluate the clarity of the lens.
Johns Hopkins Hospital
BRVO. Present by Sattar Heidari MD General ophthalmologist.
Old Fibrotic Vascular tissue in End-Stage Proliferative Retinopathy
How Diabetes Steals Vision from Your Patients
The Diabetic Retinopathy Clinical Research Network
Date of download: 9/18/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Inhibition of Neovascularization but Not Fibrosis.
Screening System for Hypertension and Diabetes at Primary Care Level
Targeted Treatments and Optimised Outcomes in Diabetic Eye Disease
Glossophobia.
PROPHYLAXIS OF MACULAR EDEMA WITH PEROPERATIVE INTRAVITREAL BEVACIZUMAB IN PATIENTS WITH DIABETIC RETINOPATHY UNDERGOING PHACOEMULSIFICATION; A RANDOMIZED.
Dr.Ravi kant Associate Professor Medicine ,AIIMS Rishikesh
J Cataract Refract Surg 2010; 36: 여의도 성모병원 R3 정연웅/Pf. 정성근
The Diabetic Retinopathy Clinical Research Network
Analysis of Macular Edema after Cataract Surgery in Patients with Diabetes Using Optical Coherence Tomography  Stephen J. Kim, MD, Robert Equi, MD, Neil.
Role of vitrectomy the treatment of diabetic macular edema
Ocular Manifestations of Diabetes
Jennifer H. Hung, MD Kristiana D. Neff, MD Department of Ophthalmology
Aliki Liaska, Dpt of Ophthalmology,
World Cornea Congress VI April 7-9, 2010
The Diabetic Retinopathy Clinical Research Network
COMPLICATIONS OF CATARACT SURGERY
Randomized Clinical Trial Jeffrey G. Gross, M.D. for the DRCR Network
DESIGN ISSUES OF A NON-INFERIORITY TRIAL
Early Experience with Descemet’s Stripping Automated Endothelial Keratoplasty Combined with Phacoemulsification: Clinical and Refractive Outcome University.
Phacoemulsification in patients with Diabetes Mellitus
In The Name of God.
Hong A, Boehlke CS, Afshari NA, Kim T Duke University Medical Center
The Diabetic Retinopathy Clinical Research Network
THERAPY FOR UVEITIS. THERAPY FOR UVEITIS OBSERVATION For development of complications For change in the appearance / severity/progression.
The Diabetic Retinopathy Clinical Research Network
Özcan R. Kayıkçıoğlu, Sinan Emre
January 16, 2019.
Intraocular lens (IOL) Dislocation
Diabetic Retinopathy Clinical Research Network
Prompt PRP vs. Ranibizumab + Deferred PRP for PDR Study
DRCR Retina Network Treatment for Center-Involved DME in Eyes with Good Visual Acuity (Protocol V)
Five-Year Experience With Routine Use of Healon5 in Cataract Surgery
The Diabetic Retinopathy Clinical Research Network
Diabetic Retinopathy Clinical Research Network
Karen Chia, MD Chan Tat Keong, MD Peter Tseng, MD Doric Wong, MD
The Diabetic Retinopathy Clinical Research Network
Presentation transcript:

بسم الله الرحمن الرحیم Cataract & Diabetes Mellitus

F. Kianersi M.D 1390 / 10 / 29

Diabetes Mellitus presently afflicts an estimated 20 Diabetes Mellitus presently afflicts an estimated 20.2 million Americans, with expectations of over 30 million cases by the year 2025.

The increased incidence of DM worldwide is accompanied by an increased risk of co-morbid conditions, including: Diabetic Retinopathy (45.9%) and Cataracts (30.6%).

These complications appeared significantly more frequently in patients with type 1 diabetes than in type 2 diabetes. Also, the disease course is more aggressive and accelerated in patients with type 1 diabetes than in those having type 2 diabetes.

Patients with Diabetes: Are 2–5 times more likely to develop cataracts than Non-Diabetic counterparts, and Tend to Experience Cataracts 10-20 years Prematurely, and Their Cataracts tend to develop more rapidly than those found in persons without Diabetes.

Cortical cataract is associated with DM, not necessarily defined by glucose control, Whereas Posterior Subcapsular Cataract (PSCC) is associated with glucose levels.

Patients with Cataracts had a higher frequency of: History of Retina Photocoagulation treatment, Higher Serum Creatinine values and Higher prevalence of Arterial Hypertension. There was a progressive increase in Cataract frequency according to the number of risk factors, starting to rise with two or more.

Cataracts may impede Fundoscopy and therefore interfere with the treatment of Diabetic Retinopathy.

Cataract Surgery Diabetic patients do experience a higher rate of surgical complications, including: Infection, Inflammation, and Cystoid Macular Edema (CME).

Cataract Surgery Historically, Cataract surgery in patients with D.M sometimes caused deleterious effects on D.R and Vision, resulting in: Progression of D.R, Progression of Macular Edema, Vitreous Hemorrhage, Neovascularization on the Iris (NVI), Worsening of Vision, or Loss of Vision.

Cataract Surgery Progress in treating D.M and D.R, along with advances in Cataract surgical techniques and Pharmacologic therapies, have vastly improved: The Safety, Efficacy and Outcomes of Cataract surgery in patients with D.M.

Cataract Surgery While advances in Cataract surgery have generally resulted in favorable surgical outcomes, Individuals with D.M have not always shared the same benefits as their Non - Diabetic counterparts.

Cataract Surgery Pre-existent Diabetic eye disease and prior Laser surgery have limited the Visual potential for patients with D.M. The presence of preoperative DR & Macular Edema and poor Renal function increased the progression of retinopathy postoperatively.

Cataract Surgery Cataract surgery in the patient with D.M presents a number of challenges in the: Pre-Surgical, Intra-Operative, and Post-Surgical stages.

Pre - Surgical Considerations

Control of Blood Glucose & other Systemic disease such as Nephropathy before surgery is mandatory. Control of any Infection such as Diabetic Foot before surgery is essential.

Multiple studies demonstrate that the level of preoperative D Multiple studies demonstrate that the level of preoperative D.R and presence of DME are accurate predictors of postoperative progression.

For these reasons, it is essential that all patients with D For these reasons, it is essential that all patients with D.M be thoroughly evaluated prior to surgery, with particular attention paid to the level of D.R and the presence of DME or Iris or Retinal Neovascularization. Also, preoperative F/A and OCT is valuable in identifying the presence and extent of D.R & CSME.

In the ETDRS, there was no statistical long-term increased risk of developing CSME, and Cataract surgery was associated with only a borderline statistically significant increased risk of D.R progression in Low-Risk patients.

However, population of Diabetic patients with Advanced forms of D However, population of Diabetic patients with Advanced forms of D.R (PDR & sever NPDR) may progress Retinopathy following Cataract surgery.

It is recommended that all active PDR be treated with full scatter laser (PRP) treatment prior to surgery. Patients with Severe NPDR should also be strongly considered for PRP prior to cataract surgery. Severe NPDR or PDR should be allowed to stabilize for approximately 6 months after laser treatment and prior to cataract surgery.

Macular Edema before surgery is the most common condition that limits post-operative visual recovery. The presence of CSME at the time of surgery is unlikely to resolve spontaneously and is more likely to result in worse vision. All CSME should be treated and allowed to resolve for 4–6 months prior to cataract surgery. In addition, DME that does not reach CSME criteria but threatens macular function should be considered for treatment.

Meticulous, appropriate, and timely Laser management of D Meticulous, appropriate, and timely Laser management of D.R and DME prior to Cataract surgery is vital to the postoperative course and outcome.

Intra - Operative Considerations

Intra - Operative Considerations Constriction of the pupil during cataract surgery is more pronounced in diabetic eyes as compared to controls. Small Pupil: Pupillary Sphincterotomy.

Intra - Operative Considerations Anterior capsular contraction is more common in Diabetic patients, especially those with Diabetic Retinopathy. Large Capsulorhexis.

Intra - Operative Considerations Supra-Hard & Brunescent Nucleus, Specially in cases who previously were undergone Vitrectomy surgery or PRP treatment.

Intra - Operative Considerations IOL

IOL Size A 6.5-mm IOL, for example, provides 39.7% larger optical area than a 5.5-mm IOL, this difference may be crucial for optimal management of DR. Large Optic IOL.

IOL Material Silicone IOLs Acrylic IOLs Hydrophilic Hydrophobic

IOL Material - Silicone Oil PCO is a frequent finding in Silicone IOLs. Silicone Oil adhere to Silicon IOLs. Thus this type of IOLs should be avoided in patients at high risk of developing advanced Diabetic Retinopathy.

IOL Material - Hydrophilic Acrylic IOLs PCO developed more frequently in Hydrophilic Acrylic IOLs. There are increasing reports of progressive Opacification of Hydrophilic Acrylic IOLs in Diabetic patients. Hydrophilic Acrylic IOLs?

IOL Material - Hydrophobic Acrylic IOLs Although Hydrophobic Acrylic IOLs were associated with more AC flare in the early postoperative period, PCO developed less frequently, especially in square edges lenses. Hydrophobic Acrylic lenses have the lowest propensity to silicone oil adhesion. Hydrophobic Acrylic IOLs may be the IOL of choice in Diabetic patients.

Post-Vitrectomy Phacoemulsification Miotic Pupil & PS, Supra-Hard Nucleus, Fluctuations of Ant. Chamber depth.

Phacoemulsification in Eyes with Silicon Oil IOL Calculation, Dense & Fibrotic Post. Capsule, Silicon oil removal via Ant. Chamber or Pars Plana, Avoid Silicon IOLs.

Pharmacologic Therapy

Pharmacologic Therapy Habib et al. have studied the use of Steroids administered at the time of Phacoemulsification surgery and found the results to be positive.

Pharmacologic Therapy Other pharmacologic choices to consider are Macugen & Avastin which was recently reported to stabilize DR with Intra - vitreal injections.

Avastin Injection

Pharmacologic Therapy Intravitreal administration of 1.25 mg Bevacizumab at the time of Cataract surgery was safe and effective in preventing the progression of DR and Diabetic Maculopathy in patients with Cataract and DR.

As expected, longer duration and complicated cataract surgery is associated with a greater risk of D.R progression and subsequent visual compromis. Therefore, it is incumbent upon the surgeon to make every effort to: Minimal Invasive, Shorter Duration, Less Inflammatory Surgery.

Post - Surgical Considerations

Post - Operative Considerations Anterior segment complications which occur more frequently in Diabetic subjects are: AC Flare, Posterior Synechiae (PS), Pupillary Block, Pigmented Precipitates on the IOL and Severe Iritis. The incidence of Fibrin reaction is high and reported in up to 13.7% of Diabetic patients.

Post - Operative Considerations Delay in Re-Epithelialization, Poor Wound Healing, Increased Risk of Endophthalmitis, Progression of D.R / M.E Post-Operatively.

Post - Operative Considerations Closed F/U in early Post Operative period and Routine F/U every 1-3 month after surgery is mandatory. Any time, N.V.I was observed or P.D.R was Progressed: Additional P.R.P and / or repeated injection of Avastin must be considered.

CME after Cataract Surgery Risk of post-operative CME in Diabetic eyes is higher than Non-Diabetic eyes. Risk of CME after cataract surgery in Diabetic eyes is higher than eyes that did not receive cataract surgery. In Diabetic patients, CME can be a frequent problem, especially in patients with preexisting D.R.

Managing CME after Cataract Surgery Suspect the diagnosis in any patient with worse than expected vision after cataract surgery. If CME is present, start with a combination of topical NSAIDs and Steroids four times a day for 6 weeks. If there is little or no response, consider sub-tenon Ttriamcinolone acetonide injection, oral NSADEs, oral Acetazolamide. If there is still little or response, consider using an intravitreal injection of Triamcinolone acetonide.

Managing CME after Cataract Surgery If there is still little or response, consider Pars Plana Vitrectomy and Internal Limiting Membrane (ILM) peeling.

Posterior Capsule Opacification (PCO) in Diabetic patients is significantly higher and more severe than Non-Diabetic patients. YAG Laser Posterior Capsulatomy in Diabetic patients may causes progression of Macular Edema and PDR and in some cases NVI may occurred.

Tips and Pearls Control of Blood Glucose & other Systemic disease, Control of any active Infection (Diabetic Foot), PRP for PDR & sever NPDR 6 months before surgery, MPC for CSME & DME 4-6 months before surgery, Meticulous & non invasive surgery,

Tips and Pearls Intra-vitreal injection of Steroid & Avastine, Closed F/U in early post operative period, Additional PRP & Avastine injection, if D.R progress or NVI appear, Proper management of post operative CME, Avoid of unnecessary Posterior Capsulatomy.

THANK YOU